Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05334316 · ClinicalTrials.gov registry record · Phase 2
Individualizing Corticosteroid Use in Pneumonia
A Phase 2 study of Pneumonia, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05334316 is a Phase 2 study of Pneumonia that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 4,519-participant average among 47 other Pneumonia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05334316, a Phase 2 study of Pneumonia, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called C- reactive protein (CRP). The overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using steroids to control inflammation in pneumonia.
Conditions Studied
Interventions
- DRUG Dexamethasone
Study Locations (1)
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05334316
The ClinicalTrials.gov registry entry for NCT05334316 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,519-participant average among 47 other Pneumonia trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which Dexamethasone is the first listed.
NCT05334316 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05334316 about?
NCT05334316 is a clinical study titled "Individualizing Corticosteroid Use in Pneumonia". In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in ...
What is the current status of trial NCT05334316?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-11-01. Estimated completion is 2027-12.
What conditions does trial NCT05334316 study?
This clinical trial studies the following conditions: Pneumonia.
What interventions are being tested in trial NCT05334316?
The interventions under investigation include: Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT05334316?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05334316 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
RECRUITING · Phase 2
-
Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia
ACTIVE NOT RECRUITING · Phase 2
-
Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia
COMPLETED · Phase 2
-
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
COMPLETED · Phase 2
-
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
COMPLETED · Phase 2
-
Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.